SSP
LGND icon

Sapphire Star Partners’s Ligand Pharmaceuticals LGND Stock Holding History

Sapphire Star Partners’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-5,519
Closed -$349K – 107
2016
Q4 		$349K Buy
+5,519
New +$348K 0.39% 43

Other funds holding LGND

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
DMK
David M. Knott $275M AUM 59.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CCMLC
Cardinal Capital Management LLC (Connecticut) Greenwich, Connecticut $365M AUM 18.32% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Sapphire Star Partners's LGND Position: Q1 2017 in Review

Sapphire Star Partners sold out of Ligand Pharmaceuticals (LGND) in Q1 2017, closing a stake of 5,519 shares — an estimated $349K sold.

Sapphire Star Partners first reported a position in LGND in Q4 2016 and held it in 1 quarter. The position peaked at $349K in Q4 2016. 257 funds tracked by Wall St. Rank hold LGND as of Q1 2017.

  • Sapphire Star Partners reported no remaining Ligand Pharmaceuticals position as of Q1 2017 after selling out during the quarter.
  • Sapphire Star Partners sold 5,519 Ligand Pharmaceuticals shares in Q1 2017, an estimated $349K.
  • Sapphire Star Partners first reported a position in Ligand Pharmaceuticals in Q4 2016 and held it in 1 quarter.
  • Sapphire Star Partners's Ligand Pharmaceuticals position peaked at $349K in Q4 2016.
  • 257 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q1 2017.

Based on Sapphire Star Partners's 13F filing for Q1 2017, filed 26 Apr 2017.